Neuralstem, Inc.  

(Public, NASDAQ:CUR)   Watch this stock  
Find more results for NYSEAMEX:CUR
0.00 (0.00%)
Jan 13 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.47 - 14.17
Open     -
Vol / Avg. 0.00/253,404.00
Mkt cap 45.06M
P/E     -
Div/yield     -
EPS -2.67
Shares 11.03M
Beta 1.66
Inst. own 9%
Mar 13, 2017
Q4 2016 Neuralstem Inc Earnings Release (Estimated) Add to calendar
Nov 8, 2016
Q3 2016 Neuralstem Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -208811.20% -200613.30%
Operating margin -196680.40% -183843.90%
EBITD margin - -180528.50%
Return on average assets -192.58% -93.33%
Return on average equity - -184.28%
Employees 11 -
CDP Score - -


20271 Goldenrod Ln
GERMANTOWN, MD 20876-4064
United States - Map
+1-301-3664841 (Phone)
+1-302-7301370 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

Officers and directors

Richard J. Daly Chairman of the Board, President, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Jonathan Lloyd Jones Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Sandford D. Smith Director
Age: 66
Bio & Compensation  - Reuters
Scott V. Ogilvie Independent Director
Age: 61
Bio & Compensation  - Reuters
William C. Oldaker Independent Director
Age: 73
Bio & Compensation  - Reuters
Catherine Angell Sohn Pharm.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Stanley I. Westreich Independent Director
Age: 78
Bio & Compensation  - Reuters